Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer DME treatment shows efficacy in phase III trial

Pfizer DME treatment shows efficacy in phase III trial

8th June 2010

Pfizer has presented results from a new clinical trial which illustrates the advantages of its new diabetic macular edema (DME) treatment over the current standard of care.

In the recent phase III study, Pfizer’s drug Macugen demonstrated superior efficacy in improving the vision of DME patients when compared to a placebo control group.

Of those in the Macugen treatment group, 37 per cent were able to gain two lines’ worth of vision on the ETDRS eye chart at 54 weeks, compared to 20 per cent on the placebo treatment.

The findings were described as significant by Pfizer, due to the current lack of any approved pharmaceutical treatments for DME.

Dr Marla Sultan, global clinical lead for Macugen at Pfizer, said: “Pfizer is pleased to be exploring Macugen as a potential treatment option to address this unmet medical need.”

Last week, Pfizer announced that it has called an early end to a clinical trial of the heart disease drug Inspra because the treatment was able to meet its primary endpoint ahead of schedule.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.